{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:16:30Z","timestamp":1773526590073,"version":"3.50.1"},"reference-count":58,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MBE"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p xml:lang=\"fr\">&lt;abstract&gt;\n\t\t\t&lt;p&gt;The aim of this study is to construct an inflammatory response-related genes (IRRGs) signature to monitor biochemical recurrence (BCR) and treatment effects in prostate cancer patients (PCa). A gene signature for inflammatory responses was constructed on the basis of the data from the Cancer Genome Atlas (TCGA) database, and validated in external datasets. It was analyzed using receiver operating characteristic curve, BCR-free survival, Cox regression, and nomogram. Distribution analysis and external model comparison were utilized. Then, enrichment analysis, tumor mutation burden, tumor immune microenvironment, and immune cell infiltration signatures were investigated. The role of the signature in immunotherapy was evaluated. The expression patterns of core genes were verified by RNA sequencing. We identified an IRRGs signature in the TCGA-PRAD cohort and verified it well in two other independent external datasets. The signature was a robust and independent prognostic index for predicting the BCR of PCa. The high-risk group of our signature predicted a shortened BCR time and an aggressive disease progression. A nomogram was constructed to predict BCR-free time in clinical practices. Neutrophils and CD8+ T cells were in higher abundance among the low-risk individuals. Immune functions varied significantly between the two groups and immune checkpoint therapy worked better for the low-risk patients. The expression of four IRRGs showed significant differences between PCa and surrounding benign tissues, and were validated in BPH-1 and DU145 cell lines by RNA sequencing. Our signature served as a reliable and promising biomarker for predicting the prognosis and evaluating the efficacy of immunotherapy, facilitating a better outcome for PCa patients.&lt;\/p&gt;\n\t\t&lt;\/abstract&gt;<\/jats:p>","DOI":"10.3934\/mbe.2022528","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:48:21Z","timestamp":1660042101000},"page":"11345-11366","source":"Crossref","is-referenced-by-count":2,"title":["Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy"],"prefix":"10.3934","volume":"19","author":[{"given":"Yong","family":"Luo","sequence":"first","affiliation":[{"name":"Department of Urology, the Second People's Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Science and Teaching, the Second People's Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, the Second People's Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weide","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Urology, the Second People's Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, China"},{"name":"Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China"},{"name":"Urology Key Laboratory of Guangdong Province, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China"},{"name":"Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China"},{"name":"State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Macau, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingbiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, the Second People's Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2321","reference":[{"key":"key-10.3934\/mbe.2022528-1","doi-asserted-by":"publisher","unstructured":"H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, <i>CA Cancer J. Clin.<\/i>, <b>71<\/b> (2021), 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"key":"key-10.3934\/mbe.2022528-2","doi-asserted-by":"publisher","unstructured":"C. Xia, X. Dong, H. Li, M. Cao, D. Sun, S. He, et al., Cancer statistics in China and United States, 2022: Profiles, trends, and determinants, <i>Chin. Med. J. Peking<\/i>, <b>135<\/b> (2022), 584\u2013590. https:\/\/doi.org\/10.1097\/CM9.0000000000002108","DOI":"10.1097\/CM9.0000000000002108"},{"key":"key-10.3934\/mbe.2022528-3","doi-asserted-by":"publisher","unstructured":"R. L. Siegel, K. D. Miller, H. E. Fuchs, A. Jemal, Cancer statistics, 2022, <i>CA Cancer J. Clin.<\/i>, <b>72<\/b> (2022), 7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","DOI":"10.3322\/caac.21708"},{"key":"key-10.3934\/mbe.2022528-4","doi-asserted-by":"publisher","unstructured":"S. R. Hawken, D. E. Spratt, J. Qi, S. M. Linsell, M. L. Cher, K. R. Ghani, et al., Utilization of salvage radiation therapy for biochemical recurrence after radical prostatectomy, <i>Int. J. Radiat. Oncol. Biol. Phys.<\/i>, <b>104<\/b> (2019), 1030\u20131034. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.006","DOI":"10.1016\/j.ijrobp.2019.01.006"},{"key":"key-10.3934\/mbe.2022528-5","doi-asserted-by":"publisher","unstructured":"J. D. Wolchok, H. Kluger, M. K. Callahan, M. A. Postow, N. A. Rizvi, A. M. Lesokhin, et al., Nivolumab plus ipilimumab in advanced melanoma, <i>N. Engl. J. Med.<\/i>, <b>369<\/b> (2013), 122\u2013133. https:\/\/doi.org\/10.1056\/NEJMoa1302369","DOI":"10.1056\/NEJMoa1302369"},{"key":"key-10.3934\/mbe.2022528-6","doi-asserted-by":"publisher","unstructured":"P. M. Ellis, E. T. Vella, Y. C. Ung, Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: A systematic review, <i>Clin. Lung Cancer<\/i>, <b>18<\/b> (2017), 444\u2013459. https:\/\/doi.org\/10.1016\/j.cllc.2017.02.001","DOI":"10.1016\/j.cllc.2017.02.001"},{"key":"key-10.3934\/mbe.2022528-7","doi-asserted-by":"publisher","unstructured":"M. Rouanne, M. Roumigui\u00e9, N. Hou\u00e9d\u00e9, A. Masson-Lecomte, P. Colin, G. Pignot, et al., Development of immunotherapy in bladder cancer: Present and future on targeting PD(L)1 and CTLA-4 pathways, <i>World J. Urol.<\/i>, <b>36<\/b> (2018), 1727\u20131740. https:\/\/doi.org\/10.1007\/s00345-018-2332-5","DOI":"10.1007\/s00345-018-2332-5"},{"key":"key-10.3934\/mbe.2022528-8","doi-asserted-by":"publisher","unstructured":"S. Venkatachalam, T. R. McFarland, N. Agarwal, U. Swami, Immune checkpoint inhibitors in prostate cancer, <i>Cancers<\/i>, <b>13<\/b> (2021), 2187. https:\/\/doi.org\/10.3390\/cancers13092187","DOI":"10.3390\/cancers13092187"},{"key":"key-10.3934\/mbe.2022528-9","doi-asserted-by":"publisher","unstructured":"F. Massari, C. Ciccarese, A. Cali\u00f2, E. Munari, L. Cima, A. B. Porcaro, et al., Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: An exploratory analysis, <i>Targeted Oncol<\/i>, <b>11<\/b> (2016), 345\u2013351. https:\/\/doi.org\/10.1007\/s11523-015-0396-3","DOI":"10.1007\/s11523-015-0396-3"},{"key":"key-10.3934\/mbe.2022528-10","doi-asserted-by":"publisher","unstructured":"W. Baas, S. Gershburg, D. Dynda, K. Delfino, K. Robinson, D. Nie, et al., Immune characterization of the programmed death receptor pathway in high risk prostate cancer, <i>Clin. Genitourin. Cancer<\/i>, <b>15<\/b> (2017), 577\u2013581. https:\/\/doi.org\/10.1016\/j.clgc.2017.04.002","DOI":"10.1016\/j.clgc.2017.04.002"},{"key":"key-10.3934\/mbe.2022528-11","doi-asserted-by":"publisher","unstructured":"R. M. Zemek, W. L. Chin, A. K. Nowak, M. J. Millward, R. A. Lake, W. J. Lesterhuis, Sensitizing the tumor microenvironment to immune checkpoint therapy, <i>Front. Immunol.<\/i>, <b>11<\/b> (2020), 223. https:\/\/doi.org\/10.3389\/fimmu.2020.00223","DOI":"10.3389\/fimmu.2020.00223"},{"key":"key-10.3934\/mbe.2022528-12","doi-asserted-by":"publisher","unstructured":"K. D. Runcie, M. C. Dallos, Prostate cancer immunotherapy-finally in from the cold? <i>Curr. Oncol. Rep.<\/i>, <b>23<\/b> (2021), 88. https:\/\/doi.org\/10.1007\/s11912-021-01084-0","DOI":"10.1007\/s11912-021-01084-0"},{"key":"key-10.3934\/mbe.2022528-13","doi-asserted-by":"publisher","unstructured":"H. Cha, J. H. Lee, S. Ponnazhagan, Revisiting immunotherapy: A focus on prostate cancer, <i>Cancer Res.<\/i>, <b>80<\/b> (2020), 1615\u20131623. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2948","DOI":"10.1158\/0008-5472.CAN-19-2948"},{"key":"key-10.3934\/mbe.2022528-14","doi-asserted-by":"publisher","unstructured":"M. Binnewies, E. W. Roberts, K. Kersten, V. Chan, D. F. Fearon, M. Merad, et al., Understanding the tumor immune microenvironment (TIME) for effective therapy, <i>Nat. Med.<\/i>, <b>24<\/b> (2018), 541\u2013550. https:\/\/doi.org\/10.1038\/s41591-018-0014-x","DOI":"10.1038\/s41591-018-0014-x"},{"key":"key-10.3934\/mbe.2022528-15","doi-asserted-by":"publisher","unstructured":"K. S. Sfanos, S. Yegnasubramanian, W. G. Nelson, A. M. De Marzo, The inflammatory microenvironment and microbiome in prostate cancer development, <i>Nat. Rev. Urol.<\/i>, <b>15<\/b> (2018), 11\u201324. https:\/\/doi.org\/10.1038\/nrurol.2017.167","DOI":"10.1038\/nrurol.2017.167"},{"key":"key-10.3934\/mbe.2022528-16","doi-asserted-by":"publisher","unstructured":"M. Archer, N. Dogra, N. Kyprianou, Inflammation as a driver of prostate cancer metastasis and therapeutic resistance, <i>Cancers<\/i>, <b>12<\/b> (2020), 2984. https:\/\/doi.org\/10.3390\/cancers12102984","DOI":"10.3390\/cancers12102984"},{"key":"key-10.3934\/mbe.2022528-17","doi-asserted-by":"publisher","unstructured":"L. Ferrero-Miliani, O. H. Nielsen, P. S. Andersen, S. E. Girardin, Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1beta generation, <i>Clin. Exp. Immunol.<\/i>, <b>147<\/b> (2007), 227\u2013235. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03261.x","DOI":"10.1111\/j.1365-2249.2006.03261.x"},{"key":"key-10.3934\/mbe.2022528-18","doi-asserted-by":"publisher","unstructured":"A. K. Tewari, J. A. Stockert, S. S. Yadav, K. K. Yadav, I. Khan, Inflammation and prostate cancer, <i>Adv. Exp. Med. Biol.<\/i>, <b>1095<\/b> (2018), 41\u201365. https:\/\/doi.org\/10.1007\/978-3-319-95693-0_3","DOI":"10.1007\/978-3-319-95693-0_3"},{"key":"key-10.3934\/mbe.2022528-19","doi-asserted-by":"publisher","unstructured":"A. Mayakonda, D. Lin, Y. Assenov, C. Plass, H. P. Koeffler, Maftools: Efficient and comprehensive analysis of somatic variants in cancer, <i>Genome<\/i> <i>Res.<\/i>, <b>28<\/b> (2018), 1747\u20131756. https:\/\/doi.org\/10.1101\/gr.239244.118","DOI":"10.1101\/gr.239244.118"},{"key":"key-10.3934\/mbe.2022528-20","doi-asserted-by":"publisher","unstructured":"H. Zhang, P. Meltzer, S. Davis, RCircos: An R package for circos 2D track plots, <i>BMC Bioinf.<\/i>, <b>14<\/b> (2013), 244. https:\/\/doi.org\/10.1186\/1471-2105-14-244","DOI":"10.1186\/1471-2105-14-244"},{"key":"key-10.3934\/mbe.2022528-21","doi-asserted-by":"publisher","unstructured":"M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, et al., Limma powers differential expression analyses for RNA-sequencing and microarray studies, <i>Nucleic Acids Res.<\/i>, <b>43<\/b> (2015), e47. https:\/\/doi.org\/10.1093\/nar\/gkv007","DOI":"10.1093\/nar\/gkv007"},{"key":"key-10.3934\/mbe.2022528-22","doi-asserted-by":"publisher","unstructured":"Y. Luo, G. Zhang, Identification of a necroptosis-related prognostic index and associated regulatory axis in kidney renal clear cell carcinoma, <i>Int. J.<\/i> <i>Gen. Med.,<\/i>  <b>15<\/b> (2022), 5407\u20135423. https:\/\/doi.org\/10.2147\/IJGM.S367173","DOI":"10.2147\/IJGM.S367173"},{"key":"key-10.3934\/mbe.2022528-23","doi-asserted-by":"crossref","unstructured":"<i>Gene Ontology Consortium<\/i>, Gene Ontology Consortium: Going forward, <i>Nucleic Acids Res.<\/i>, <b>43<\/b> (2015), D1049\u2013D1056. <a href=\"https:\/\/doi.org\/10.1093\/nar\/gku1179\" target=\"_blank\">https:\/\/doi.org\/10.1093\/nar\/gku1179<\/a>","DOI":"10.1093\/nar\/gku1179"},{"key":"key-10.3934\/mbe.2022528-24","doi-asserted-by":"publisher","unstructured":"G. Yu, L. Wang, Y. Han, Q. He, ClusterProfiler: An R package for comparing biological themes among gene clusters, <i>Omics J.<\/i> <i>Integr. Biol.<\/i>, <b>16<\/b> (2012), 284\u2013287. https:\/\/doi.org\/10.1089\/omi.2011.0118","DOI":"10.1089\/omi.2011.0118"},{"key":"key-10.3934\/mbe.2022528-25","doi-asserted-by":"publisher","unstructured":"M. Kanehisa, S. Goto, KEGG: Kyoto encyclopedia of genes and genomes, <i>Nucleic Acids Res.<\/i>, <b>28<\/b> (2000), 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27","DOI":"10.1093\/nar\/28.1.27"},{"key":"key-10.3934\/mbe.2022528-26","doi-asserted-by":"publisher","unstructured":"T. Li, J. Fan, B. Wang, N. Traugh, Q. Chen, J. S. Liu, et al., TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells, <i>Cancer Res.<\/i>, <b>77<\/b> (2017), e108\u2013e110. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307","DOI":"10.1158\/0008-5472.CAN-17-0307"},{"key":"key-10.3934\/mbe.2022528-27","doi-asserted-by":"publisher","unstructured":"Y. Luo, Q. Chen, J. Lin, Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma, <i>Math. Biosci. Eng.<\/i>, <b>19<\/b> (2022), 7055\u20137075. https:\/\/doi.org\/10.3934\/mbe.2022333","DOI":"10.3934\/mbe.2022333"},{"key":"key-10.3934\/mbe.2022528-28","doi-asserted-by":"publisher","unstructured":"A. Grosset, V. Ouellet, C. Caron, G. Fragoso, V. Barr\u00e8s, N. Delvoye, et al., Validation of the prognostic value of NF-\u03baB P65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian prostate cancer biomarker network, <i>PLoS Med.<\/i>, <b>16<\/b> (2019), e1002847. https:\/\/doi.org\/10.1371\/journal.pmed.1002847","DOI":"10.1371\/journal.pmed.1002847"},{"key":"key-10.3934\/mbe.2022528-29","doi-asserted-by":"publisher","unstructured":"H. Xu, Q. Ding, H. Jiang, Genetic Polymorphism of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer risk, <i>Asian Pac.<\/i> <i>J. Cancer Prev.<\/i>, <b>15<\/b> (2014), 8741\u20138747. https:\/\/doi.org\/10.7314\/apjcp.2014.15.20.8741","DOI":"10.7314\/apjcp.2014.15.20.8741"},{"key":"key-10.3934\/mbe.2022528-30","doi-asserted-by":"publisher","unstructured":"J. P. Corradi, C. W. Cumarasamy, I. Staff, J. Tortora, A. Salner, T. McLaughlin, et al., Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy, <i>Prostate<\/i>, <b>81<\/b> (2021), 694\u2013702. https:\/\/doi.org\/10.1002\/pros.24150","DOI":"10.1002\/pros.24150"},{"key":"key-10.3934\/mbe.2022528-31","doi-asserted-by":"publisher","unstructured":"S. Ge, X. Hua, J. Chen, H. Xiao, L. Zhang, J. Zhou, et al., Identification of a costimulatory molecule-related signature for predicting prognostic risk in prostate cancer, <i>Front. Genet.<\/i>, <b>12<\/b> (2021), 666300. https:\/\/doi.org\/10.3389\/fgene.2021.666300","DOI":"10.3389\/fgene.2021.666300"},{"key":"key-10.3934\/mbe.2022528-32","doi-asserted-by":"publisher","unstructured":"H. Liu, L. Gao, T. Xie, J. Li, T. Zhai, Y. Xu, Identification and validation of a prognostic signature for prostate cancer based on ferroptosis-related genes, <i>Front. Oncol.<\/i>, <b>11<\/b> (2021), 623313. https:\/\/doi.org\/10.3389\/fonc.2021.623313","DOI":"10.3389\/fonc.2021.623313"},{"key":"key-10.3934\/mbe.2022528-33","doi-asserted-by":"publisher","unstructured":"Z. Sun, Y. Mao, X. Zhang, S. Lu, H. Wang, C. Zhang, et al., Identification of ARHGEF38, NETO2, GOLM1, and SAPCD2 associated with prostate cancer progression by bioinformatic analysis and experimental validation, <i>Front. Cell<\/i> <i>Dev. Biol.<\/i>, <b>9<\/b> (2021), 718638. https:\/\/doi.org\/10.3389\/fcell.2021.718638","DOI":"10.3389\/fcell.2021.718638"},{"key":"key-10.3934\/mbe.2022528-34","doi-asserted-by":"publisher","unstructured":"H. Zhao, Y. Zeng, Z. Han, Y. Zhuo, Y. Liang, C. T. Hon, et al., Novel immune-related signature for risk stratification and prognosis in prostatic adenocarcinoma, <i>Cancer Sci.<\/i>, <b>112<\/b> (2021), 4365\u20134376. https:\/\/doi.org\/10.1111\/cas.15062","DOI":"10.1111\/cas.15062"},{"key":"key-10.3934\/mbe.2022528-35","doi-asserted-by":"publisher","unstructured":"S. E. Jalava, A. Urbanucci, L. Latonen, K. K. Waltering, B. Sahu, O. A. J\u00e4nne, et al., Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer, <i>Oncogene<\/i>, <b>31<\/b> (2012), 4460\u20134471. https:\/\/doi.org\/10.1038\/onc.2011.624","DOI":"10.1038\/onc.2011.624"},{"key":"key-10.3934\/mbe.2022528-36","doi-asserted-by":"publisher","unstructured":"P. Liu, Y. Liang, L. Jiang, H. Wang, S. Wang, J. Dong, CX3CL1\/fractalkine enhances prostate cancer spinal metastasis by activating the Src\/FAK pathway, <i>Int. J. Oncol.<\/i>, <b>53<\/b> (2018), 1544\u20131556. https:\/\/doi.org\/10.3892\/ijo.2018.4487","DOI":"10.3892\/ijo.2018.4487"},{"key":"key-10.3934\/mbe.2022528-37","doi-asserted-by":"publisher","unstructured":"S. Chen, M. Huang, X. Hu, Interference with KCNJ2 inhibits proliferation, migration and EMT progression of apillary thyroid carcinoma cells by upregulating GNG2 expression, <i>Mol. Med. Rep.<\/i>, <b>24<\/b> (2021), 1\u201310. https:\/\/doi.org\/10.3892\/mmr.2021.12261","DOI":"10.3892\/mmr.2021.12261"},{"key":"key-10.3934\/mbe.2022528-38","doi-asserted-by":"publisher","unstructured":"C. Ji, Y. Wang, D. Xiang, Q. Liu, Z. Zhou, F. Qian, et al., Kir2.1 interaction with Stk38 promotes invasion and metastasis of human gastric cancer by enhancing MEKK2-MEK1\/2-ERK1\/2 signaling, <i>Cancer Res.<\/i>, <b>78<\/b> (2018), 3041\u20133053. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3776","DOI":"10.1158\/0008-5472.CAN-17-3776"},{"key":"key-10.3934\/mbe.2022528-39","doi-asserted-by":"publisher","unstructured":"L. Liesenfeld, M. Kron, J. E. Gschwend, K. Herkommer, Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy, <i>J.<\/i> <i>Urol.<\/i>, <b>197<\/b> (2017), 143\u2013148. https:\/\/doi.org\/10.1016\/j.juro.2016.07.004","DOI":"10.1016\/j.juro.2016.07.004"},{"key":"key-10.3934\/mbe.2022528-40","doi-asserted-by":"publisher","unstructured":"C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, P. C. Walsh, Natural history of progression after PSA elevation following radical prostatectomy, <i>JAMA<\/i>, <b>281<\/b> (1999), 1591\u20131597. https:\/\/doi.org\/10.1001\/jama.281.17.1591","DOI":"10.1001\/jama.281.17.1591"},{"key":"key-10.3934\/mbe.2022528-41","doi-asserted-by":"publisher","unstructured":"S. Shen, R. Zhang, Y. Jiang, Y. Li, L. Lin, Z. Liu, et al., Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types, <i>Mol. Cancer<\/i>, <b>20<\/b> (2021), 67. https:\/\/doi.org\/10.1186\/s12943-021-01362-2","DOI":"10.1186\/s12943-021-01362-2"},{"key":"key-10.3934\/mbe.2022528-42","doi-asserted-by":"publisher","unstructured":"T. Wu, Y. Dai, Tumor microenvironment and therapeutic response, <i>Cancer Lett.<\/i>, <b>387<\/b> (2017), 61\u201368. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.043","DOI":"10.1016\/j.canlet.2016.01.043"},{"key":"key-10.3934\/mbe.2022528-43","doi-asserted-by":"publisher","unstructured":"M. St Paul, P. S. Ohashi, The roles of CD8(+) T cell subsets in antitumor immunity, <i>Trends Cell Biol.<\/i>, <b>30<\/b> (2020), 695\u2013704. https:\/\/doi.org\/10.1016\/j.tcb.2020.06.003","DOI":"10.1016\/j.tcb.2020.06.003"},{"key":"key-10.3934\/mbe.2022528-44","doi-asserted-by":"publisher","unstructured":"M. Philip, A. Schietinger, CD8(+) T cell differentiation and dysfunction in cancer, <i>Nat. Rev. Immunol.<\/i>, <b>22<\/b> (2022), 209\u2013223. https:\/\/doi.org\/10.1038\/s41577-021-00574-3","DOI":"10.1038\/s41577-021-00574-3"},{"key":"key-10.3934\/mbe.2022528-45","doi-asserted-by":"publisher","unstructured":"J. Qiao, Z. Liu, C. Dong, Y. Luan, A. Zhang, C. Moore, et al., Targeting tumors with IL-10 prevents dendritic cell-mediated CD8(+) T cell apoptosis, <i>Cancer Cell<\/i>, <b>35<\/b> (2019), 901\u2013915. https:\/\/doi.org\/10.1016\/j.ccell.2019.05.005","DOI":"10.1016\/j.ccell.2019.05.005"},{"key":"key-10.3934\/mbe.2022528-46","doi-asserted-by":"publisher","unstructured":"G. M. Lynn, C. Sedlik, F. Baharom, Y. Zhu, R. A. Ramirez-Valdez, V. L. Coble, et al., Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens, <i>Nat. Biotechnol.<\/i>, <b>38<\/b> (2020), 320\u2013332. https:\/\/doi.org\/10.1038\/s41587-019-0390-x","DOI":"10.1038\/s41587-019-0390-x"},{"key":"key-10.3934\/mbe.2022528-47","doi-asserted-by":"publisher","unstructured":"S. Wang, W. Su, C. Zhong, T. Yang, W. Chen, G. Chen, et al., An eight-circRNA assessment model for predicting biochemical recurrence in prostate cancer, <i>Front. Cell Dev. Biol.<\/i>, <b>8<\/b> (2020), 599494. https:\/\/doi.org\/10.3389\/fcell.2020.599494","DOI":"10.3389\/fcell.2020.599494"},{"key":"key-10.3934\/mbe.2022528-48","doi-asserted-by":"publisher","unstructured":"Y. Yanai, T. Kosaka, S. Mikami, H. Hongo, Y. Yasumizu, T. Takeda, et al., CD8-positive T cells and CD204-positive M2-like macrophages predict postoperative prognosis of very high-risk prostate cancer, <i>Sci. Rep.<\/i>, <b>11<\/b> (2021), 22495. https:\/\/doi.org\/10.1038\/s41598-021-01900-4","DOI":"10.1038\/s41598-021-01900-4"},{"key":"key-10.3934\/mbe.2022528-49","doi-asserted-by":"publisher","unstructured":"J. R. Lees, B. Charbonneau, J. D. Hayball, K. Diener, M. Brown, R. Matusik, et al., T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction, <i>Prostate<\/i>, <b>66<\/b> (2006), 578\u2013590. https:\/\/doi.org\/10.1002\/pros.20307","DOI":"10.1002\/pros.20307"},{"key":"key-10.3934\/mbe.2022528-50","doi-asserted-by":"publisher","unstructured":"V. R. de Porras, J. C. Pardo, L. Notario, O. Etxaniz, A. Font, Immune checkpoint inhibitors: A promising treatment option for metastatic castration-resistant prostate cancer, <i>Int. J. Mol. Sci.<\/i>, <b>22<\/b> (2021), 4712. https:\/\/doi.org\/10.3390\/ijms22094712","DOI":"10.3390\/ijms22094712"},{"key":"key-10.3934\/mbe.2022528-51","doi-asserted-by":"publisher","unstructured":"M. Bilusic, R. A. Madan, J. L. Gulley, Immunotherapy of prostate cancer: Facts and hopes, <i>Clin. Cancer Res.<\/i>, <b>23<\/b> (2017), 6764\u20136770. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0019","DOI":"10.1158\/1078-0432.CCR-17-0019"},{"key":"key-10.3934\/mbe.2022528-52","doi-asserted-by":"publisher","unstructured":"E. S. Antonarakis, J. M. Piulats, M. Gross-Goupil, J. Goh, K. Ojamaa, C. J. Hoimes, et al., Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase \u2161 KEYNOTE-199 study, <i>J. Clin. Oncol.<\/i>, <b>38<\/b> (2020), 395\u2013405. https:\/\/doi.org\/10.1200\/JCO.19.01638","DOI":"10.1200\/JCO.19.01638"},{"key":"key-10.3934\/mbe.2022528-53","doi-asserted-by":"publisher","unstructured":"A. R. Hansen, C. Massard, P. A. Ott, N. B. Haas, J. S. Lopez, S. Ejadi, et al., Pembrolizumab for advanced prostate adenocarcinoma: Findings of the KEYNOTE-028 study, <i>Ann. Oncol.<\/i>, <b>29<\/b> (2018), 1807\u20131813. https:\/\/doi.org\/10.1093\/annonc\/mdy232","DOI":"10.1093\/annonc\/mdy232"},{"key":"key-10.3934\/mbe.2022528-54","doi-asserted-by":"publisher","unstructured":"R. Mo, Z. Han, Y. Liang, J. Ye, S. Wu, S. X. Lin, et al., Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8(+) tumor-associated lymphocytes and poor prognosis in prostate cancer, <i>Int. J. Cancer<\/i>, <b>144<\/b> (2019), 3099\u20133110. https:\/\/doi.org\/10.1002\/ijc.32061","DOI":"10.1002\/ijc.32061"},{"key":"key-10.3934\/mbe.2022528-55","doi-asserted-by":"publisher","unstructured":"F. Petitprez, N. Fossati, Y. Vano, M. Freschi, E. Becht, R. Lucian\u00f2, et al., PD-L1 expression and CD8(+) T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer, <i>Eur. Urol.<\/i> <i>Focus<\/i>, <b>5<\/b> (2019), 192\u2013196. https:\/\/doi.org\/10.1016\/j.euf.2017.05.013","DOI":"10.1016\/j.euf.2017.05.013"},{"key":"key-10.3934\/mbe.2022528-56","doi-asserted-by":"publisher","unstructured":"C. Vicier, P. Ravi, L. Kwak, L. Werner, Y. Huang, C. Evan, et al., Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer, <i>Prostate<\/i>, <b>81<\/b> (2021), 50\u201357. https:\/\/doi.org\/10.1002\/pros.24079","DOI":"10.1002\/pros.24079"},{"key":"key-10.3934\/mbe.2022528-57","doi-asserted-by":"publisher","unstructured":"H. Gevensleben, D. Dietrich, C. Golletz, S. Steiner, M. Jung, T. Thiesler, et al., The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer, <i>Clin. Cancer Res.<\/i>, <b>22<\/b> (2016), 1969\u20131977. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2042","DOI":"10.1158\/1078-0432.CCR-15-2042"},{"key":"key-10.3934\/mbe.2022528-58","doi-asserted-by":"publisher","unstructured":"B. T. Rekoske, B. M. Olson, D. G. McNeel, Antitumor vaccination of prostate cancer patients elicits PD-1\/PD-L1 regulated antigen-specific immune responses, <i>Oncoimmunology<\/i>, <b>5<\/b> (2016), e1165377. https:\/\/doi.org\/10.1080\/2162402X.2016.1165377","DOI":"10.1080\/2162402X.2016.1165377"}],"container-title":["Mathematical Biosciences and Engineering"],"original-title":[],"link":[{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2022528?viewType=html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T01:48:22Z","timestamp":1660096102000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2022528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.3934\/mbe.2022528","relation":{},"ISSN":["1551-0018"],"issn-type":[{"value":"1551-0018","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}